inclusion criteria: * hospitalized male or female subjects of ≥ 18 years of age at time of screening who are being treated in the intensive care unit (icu) for covid-19 for not longer than 48 hours or for whom a decision has been made that covid-19 disease severity warrants icu admission. * subject (or a legal representative or a nearest relative or a relative by marriage, as appropriate) provides informed consent (icf) prior to initiation of any study procedures. * has laboratory-confirmed novel coronavirus (sars-cov-2) infection as determined by qualitative polymerase chain reaction (pcr) (reverse transcriptase \[rt\]-pcr), or other commercial or public health assay in any specimen during the current hospital admission prior to randomization. * illness (symptoms) of any duration, and the following: 1. radiographic infiltrates by imaging (chest x-ray, computerized tomography \[ct\] scan, etc.), and 2. requiring mechanical ventilation and/or supplemental oxygen * subjects with no limitation of therapeutic effort (decision on the status and future of the subject). * female subjects of child-bearing potential must have a negative test for pregnancy blood or urine human chorionic gonadotropin (hcg)-based assay at screening/baseline visit.

inclusion criteria: * hospitalized male or female subjects of ≥ 18 years of age at time of screening who are being treated in the intensive care unit (icu) for covid-19 for not longer than 48 hours or for whom a decision has been made that covid-19 disease severity warrants icu admission. * subject (or a legal representative or a nearest relative or a relative by marriage, as appropriate) provides informed consent (icf) prior to initiation of any study procedures. * has laboratory-confirmed novel coronavirus (sars-cov-2) infection as determined by qualitative polymerase chain reaction (pcr) (reverse transcriptase \[rt\]-pcr), or other commercial or public health assay in any specimen during the current hospital admission prior to randomization. * illness (symptoms) of any duration, and the following: 1. radiographic infiltrates by imaging (chest x-ray, computerized tomography \[ct\] scan, etc.), and 2. requiring mechanical ventilation and/or supplemental oxygen * subjects with no limitation of therapeutic effort (decision on the status and future of the subject). * female subjects of child-bearing potential must have a negative test for pregnancy blood or urine human chorionic gonadotropin (hcg)-based assay at screening/baseline visit.

inclusion criteria: hospitalized male or female subjects of ≥ 18 years of age at time of screening who are being treated in the intensive care unit (icu) for covid-19 for not longer than 48 hours or for whom a decision has been made that covid-19 disease severity warrants icu admission. subject (or a legal representative or a nearest relative or a relative by marriage, as appropriate) provides informed consent (icf) prior to initiation of any study procedures. has laboratory-confirmed novel coronavirus (sars-cov-2) infection as determined by qualitative polymerase chain reaction (pcr) (reverse transcriptase [rt]-pcr), or other commercial or public health assay in any specimen during the current hospital admission prior to randomization. illness (symptoms) of any duration, and the following: radiographic infiltrates by imaging (chest x-ray, computerized tomography [ct] scan, etc.), and requiring mechanical ventilation and/or supplemental oxygen subjects with no limitation of therapeutic effort (decision on the status and future of the subject). female subjects of child-bearing potential must have a negative test for pregnancy blood or urine human chorionic gonadotropin (hcg)-based assay at screening/baseline visit.

inclusion criteria: hospitalized male or female subjects of ≥ 18 years of age at time of screening who are being treated in the intensive care unit (icu) for covid-19 for not longer than 48 hours or for whom a decision has been made that covid-19 disease severity warrants icu admission. subject (or a legal representative or a nearest relative or a relative by marriage, as appropriate) provides informed consent (icf) prior to initiation of any study procedures. has laboratory-confirmed novel coronavirus (sars-cov-2) infection as determined by qualitative polymerase chain reaction (pcr) (reverse transcriptase [rt]-pcr), or other commercial or public health assay in any specimen during the current hospital admission prior to randomization. illness (symptoms) of any duration, and the following: radiographic infiltrates by imaging (chest x-ray, computerized tomography [ct] scan, etc.), and requiring mechanical ventilation and/or supplemental oxygen subjects with no limitation of therapeutic effort (decision on the status and future of the subject). female subjects of child-bearing potential must have a negative test for pregnancy blood or urine human chorionic gonadotropin (hcg)-based assay at screening/baseline visit.

inclusion criteria: - hospitalized male or female subjects of ≥ 18 years of age at time of screening who are being treated in the intensive care unit (icu) for covid-19 for not longer than 48 hours or for whom a decision has been made that covid-19 disease severity warrants icu admission. - subject (or a legal representative or a nearest relative or a relative by marriage, as appropriate) provides informed consent (icf) prior to initiation of any study procedures. - has laboratory-confirmed novel coronavirus (sars-cov-2) infection as determined by qualitative polymerase chain reaction (pcr) (reverse transcriptase [rt]-pcr), or other commercial or public health assay in any specimen during the current hospital admission prior to randomization. - illness (symptoms) of any duration, and the following: 1. radiographic infiltrates by imaging (chest x-ray, computerized tomography [ct] scan, etc.), and 2. requiring mechanical ventilation and/or supplemental oxygen - subjects with no limitation of therapeutic effort (decision on the status and future of the subject). - female subjects of child-bearing potential must have a negative test for pregnancy blood or urine human chorionic gonadotropin (hcg)-based assay at screening/baseline visit.

inclusion criteria: - hospitalized male or female subjects of ≥ 18 years of age at time of screening who are being treated in the intensive care unit (icu) for covid-19 for not longer than 48 hours or for whom a decision has been made that covid-19 disease severity warrants icu admission. - subject (or a legal representative or a nearest relative or a relative by marriage, as appropriate) provides informed consent (icf) prior to initiation of any study procedures. - has laboratory-confirmed novel coronavirus (sars-cov-2) infection as determined by qualitative polymerase chain reaction (pcr) (reverse transcriptase [rt]-pcr), or other commercial or public health assay in any specimen during the current hospital admission prior to randomization. - illness (symptoms) of any duration, and the following: 1. radiographic infiltrates by imaging (chest x-ray, computerized tomography [ct] scan, etc.), and 2. requiring mechanical ventilation and/or supplemental oxygen - subjects with no limitation of therapeutic effort (decision on the status and future of the subject). - female subjects of child-bearing potential must have a negative test for pregnancy blood or urine human chorionic gonadotropin (hcg)-based assay at screening/baseline visit.